Valuation: Satellos Bioscience Inc.

Market Cap 160M 140M 129M 120M 227M 15.23B 231M 1.54B 600M 7.49B 601M 588M 25.81B P/E 2026 *
-4.48x
P/E 2027 * -4.77x
Enterprise Value 66.36M 58.01M 53.31M 49.69M 94.25M 6.32B 95.68M 640M 249M 3.11B 249M 244M 10.7B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
1 day+6.96%
1 week+6.96%
Current month+2.35%
1 month+31.29%
3 months+32.24%
6 months+29.88%
Current year+37.75%
1 week 10.17
Extreme 10.17
11.51
1 month 7.76
Extreme 7.76
11.51
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 28/02/2018
Chief Tech/Sci/R&D Officer - 30/04/2018
Director of Finance/CFO - 31/08/2023
Director TitleAgeSince
Chairman 59 30/06/2018
Director/Board Member 50 28/02/2018
Director/Board Member 70 30/06/2012
Date Insider Type Main position Quantity % Market Cap.
06-17Buy

Director

15,000 0.0720%
04-06Option

Founder

108,630 0.7027%
04-06Buy

Director

5,500 0.0356%
Change 5-day change 1-year change 3-year change Capi.($)
+6.96%+6.96%+44.31%+93.44% 160M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +3.28%+8.41%+53.60%+141.97% 24.56B
Weighted average by Cap. +2.47%+6.47%+59.05%+137.68%

Financials

2026 *2027 *
Net sales - -
Net income -43.2M -37.76M -34.7M -32.35M -61.35M -4.11B -62.28M -417M -162M -2.02B -162M -159M -6.97B -57.06M -49.88M -45.84M -42.73M -81.04M -5.43B -82.27M -550M -214M -2.67B -214M -210M -9.2B
Net Debt -93.65M -81.87M -75.24M -70.13M -133M -8.92B -135M -903M -351M -4.38B -352M -344M -15.1B -111M -97.34M -89.46M -83.38M -158M -10.6B -161M -1.07B -417M -5.21B -418M -409M -17.96B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
03/07/26 CA$10.91 +6.96% 2,030
02/07/26 CA$10.20 -4.32% 2,233
30/06/26 CA$10.66 -5.24% 129,744
29/06/26 CA$11.25 +10.29% 74,298
26/06/26 CA$10.20 +6.03% 10,782
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.91CAD
Average target price
15.33CAD
Spread / Average Target
+40.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock